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Summary
In this study, we determined conditions leading to the
development of colitis in mice with nucleotide binding
oligomerizationdomain2 (NOD2)deficiency, a suscep-
tibility factor in Crohn’s disease. We found that NOD2-
deficient antigen-presenting cells (APCs) produced in-
creased amounts of interleukin (IL)-12 in the presence
of ovalbumin (OVA) peptide and peptidoglycan or re-
combinant E. coli that express OVA peptide (ECOVA).
Furthermore, these APCs elicited heightened inter-
feron-g (IFN-g) responses from cocultured OVA-spe-
cific CD4+ T cells. We then demonstrated that NOD2-
deficient mice adoptively transferred OVA-specific
CD4+ T cells and that administered intrarectal ECOVA
developed colitis associated with the expansion of
OVA-specific CD4+ T cells producing IFN-g. Impor-
tantly, this colitis was highly dependent on Toll-like re-
ceptor 2 (TLR2) function since it was suppressed in
NOD2 and TLR2 double-deficient mice. Thus, NOD2-
deficientmice become susceptible to colitis as a result
of increased TLR2 responses when they have the ca-
pacity to respond to an antigen expressed by mucosal
bacteria.
Introduction
A subgroup of patients with Crohn’s disease bear mu-
tations of CARD15, a gene that encodes nucleotide
binding oligomerization domain 2 (NOD2) (Hugot
et al., 2001; Ogura et al., 2001; Lesage et al., 2002).
NOD2 belongs to the NOD-LRR (leucine-rich-repeat)
family of proteins, whose members are characterized
by a tripartite domain structure consisting of a car-
boxy-terminal recognition LRR domain, a central NOD
*Correspondence: wstrober@niaid.nih.govdomain, and an amino-terminal domain composed of
protein-protein interaction cassettes, such as caspase
recruitment domains (CARDs) or pyrin domains
(Strober et al., 2006; Watanabe et al., 2005a). NOD2 is
expressed in the cytoplasmic region of antigen-pre-
senting cells (APCs) (Gutierrez et al., 2002) and epithe-
lial cells (Hisamatsu et al., 2003), and its LRR domain
serves as a receptor for muramyl dipeptide (MDP),
a small molecule derived from bacterial cell wall pepti-
doglycan (PGN) (Girardin et al., 2003; Inohara et al.,
2003). Stimulation of NOD2 with MDP leads to activa-
tion of the serine-threonine kinase, Receptor-interact-
ing protein (RIP)-like interacting caspase-like apoptosis
regulatory protein kinase (RICK) via a CARD-CARD
interaction that, in turn, results in ubiquitinylation of
NF-kB essential Modulator (NEMO) and translocation
of nuclear factor-kappa B (NF-kB) subunit into the
nucleus (Abbott et al., 2004; Ogura et al., 2001). Thus,
one outcome of NOD2 activation by MDP is the activa-
tion of the NF-kB pathway.
It is not at all clear, however, that this function of
NOD2 is responsible for the susceptibility to Crohn’s
disease in patients with NOD2 mutations. On the one
hand, human embryonic kidney 293 cells expressing
the mutated NOD2 associated with Crohn’s disease
exhibit defective NF-kB activation after stimulation
with MDP (Inohara et al., 2003) and, on the other, in-
creased production of NF-kB-related Th1 cytokines
such as IL-12 and IFN-g plays an indispensable role
in the development of intestinal inflammation in
Crohn’s disease (Bouma and Strober, 2003; Strober
et al., 2002). In a previous study, we attempted to re-
solve this paradox with the use of murine APCs lacking
NOD2 or expressing the mutated NOD2 associated
with Crohn’s disease (Watanabe et al., 2004). We found
that PGN induction of IL-12 is normally downregulated
by concomitant stimulation of NOD2 via the PGN com-
ponent, MDP. Thus, in the absence of NOD2 or in
the presence of Crohn’s disease-associated mutated
NOD2, PGN elicits an excessive NF-kB-dependent IL-
12 response (Watanabe et al., 2004), suggesting that
an unregulated innate immune response to a ubiquitous
component of the intestinal microflora could at least
partially account for the robust Th1 response causing
inflammatory bowel disease (IBD) in patients with NOD2
mutations.
The above studies, however, left unanswered the
question of whether the dysregulated innate IL-12 re-
sponse resulting from NOD2 deficiency was sufficient
for the occurrence of IBD or whether adaptive re-
sponses mediated by T cells also played an essential
role (Bouma and Strober, 2003; Strober et al., 2002).
Therefore, in the current studies we addressed the
question of whether the excessive IL-12 response to
PGN occurring in the absence of NOD2 signaling also
supports a strong adaptive IFN-g response by antigen
(Ag)-specific CD4+ T cells and whether such an adap-
tive response could lead to mucosal inflammation if
the stimulating Ag were a component of a mucosal
organism.
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PGN-Stimulated NOD2-Deficient APCs Enhanced
IFN-g Responses by Ag-Specific CD4+ T Cells
In a previous paper, we reported that PGN-stimulated
splenic CD11b+ cells from NOD2-deficient (Card152/2)
mice produce increased amounts of IL-12 as compared
to cells from NOD2-intact (Card15+/+) (littermate control)
mice (Watanabe et al., 2004). Since IL-12 plays a pivotal
role in the differentiation of Th1 cells, we addressed in
the present study whether this enhanced production of
IL-12 by NOD2-deficient APCs affects production of cy-
tokines by naive Ag-specific CD4+ T cells. In initial stud-
ies to explore this question, CD4+ T cells recognizing the
323–339 peptide fragment of ovalbumin (OVA323-339
peptide) in the context of IAb were isolated from OT-II
transgenic mice (Kondrack et al., 2003) and then stimu-
lated in vitro with OVA323-339 peptide presented by
splenic CD11b+ cells from NOD2-deficient or NOD2-
intact mice (Pauleau and Murray, 2003) in the presence
of various TLR or NOD ligands: lipopolysaccharide
(LPS), a TLR4 ligand; PGN from Staphylococcus aureus
(PGN S), PGN from Escherichia coli (PGN E), and
Pam3CSK4 (Pam), TLR2 ligands; double stranded RNA
(dsRNA), a TLR3 ligand; Flagellin, a TLR5 ligand; Loxor-
ibine (Lox), a TLR7 ligand; CpG, a TLR9 ligand; and
muramyl dipeptide (MDP), a NOD2 ligand.
As mentioned above, our previous studies had shown
that PGN-stimulated IL-12 production via TLR2 signal-
ing is negatively regulated by MDP-mediated activation
of NOD2 signaling, and this negative regulation is re-
leased in the absence of intact NOD2 signaling. Consis-
tent with this, IL-12p70 production is enhanced in cul-
tures of PGN-stimulated splenic CD11b+ cells from
NOD2-deficient mice compared with cells from litter-
mate control mice (Figure 1A). In addition, such produc-
tion is further enhanced when OVA-specific CD4+ T cells
and OVA323-339 peptide are added to cultures containing
NOD2-deficient APCs but not to cultures containing
NOD2-intact APCs. As suggested by studies of CD40 li-
gand-deficient mice, this further enhancement may be
due to the fact that CD40 and CD40 ligand interaction
between Ag-activated T cells and APCs plays a critical
role in IL-12 production by the latter cells (Campbell
et al., 1996; Kamanaka et al., 1996). Although addition
of OVA323-339 peptide and OVA-specific CD4
+ T cells to
LPS (TLR4)-stimulated cultures and, to a lesser extent,
to CpG (TLR9)-stimulated cultures led to enhanced IL-
12 secretion, in this case, no difference in IL-12 secre-
tion between cultures containing NOD2-deficient and
NOD2-intact APCs was seen.
To address the specificity of NOD2 signaling in the
regulation of PGN-mediated TLR2 responses, we stimu-
lated CD11b+ cells with Pam3CSK4, a TLR2 ligand that
unlike PGN does not contain MDP and therefore does
not result in simultaneous TLR2 and NOD2 signaling.
We found that whereas CD11b+ cells from NOD2-intact
and NOD2-deficient mice produced equivalent amounts
of IL-12p70 when stimulated with Pam3CSK4 alone,
cells from NOD2-intact mice produced significantly
less IL-12p70 than cells from NOD2-deficient mice when
stimulated with 1 mg/ml of Pam3CSK4 plus 100 mg/ml
of MDP (IL-12p70 production in pg/ml by NOD2-intact
cells versus NOD2-deficient cells, Pam3CSK4 stimula-tion alone: 136.06 10.1 versus 113.06 15.0; Pam3CSK4
plus MDP stimulation: 53.0 6 3.1 versus 107.0 6 6.7,
p < 0.01). These studies show that TLR2 signaling
is regulated by a ligand specific for NOD2, MDP. In
related studies, we showed that PGN (10 mg/ml) stim-
ulation of CD11b+ cells from NOD1-deficient mice (Viala
et al., 2004), unlike those from NOD2-deficient mice, ex-
hibit equivalent IL-12p70 production compared to litter-
mate control mice (IL-12p70 production in pg/ml by
NOD1-intact cells versus NOD1-deficient cells, 92.5 6
5.9 versus 94.66 2.9). Thus, the regulation of TLR2 stim-
ulation does not occur in relation to a NOD protein
(NOD1) with a similar structure to NOD2, further support-
ing the specificity of NOD2 for such regulation.
Having defined the cytokine responses of NOD2-defi-
cient APCs to PGN and other TLR agonists during pre-
sentation of Ag to cocultured Ag-specific CD4+ T cells,
we were in a position to evaluate the responses of the
cocultured T cells. Not surprisingly, IFN-g production
by the latter cells, regardless of the type of stimulating
TLR ligand present, occurred only in cultures containing
OVA323-339 peptide, i.e., the stimulant of the Ag-specific
T cells was present (Figure 1B). However, in PGN-stim-
ulated cultures, NOD2-deficient APCs led to markedly
greater IFN-g production than NOD2-intact APCs,
whereas in cultures stimulated by other TLR ligands,
no difference between cultures containing NOD2-defi-
cient and NOD2-intact APCs was seen. In addition, as
shown in Figure 1C, in cultures of PGN-stimulated
NOD2-deficient APCs containing OVA323-339 peptide,
Ag-specific CD4+ T cells produced significantly less IL-
13 than in equivalent cultures containing PGN-stimu-
lated NOD2-intact APCs, whereas cultures containing
NOD2-deficient and NOD2-intact APCs produced equiv-
alent amounts of IL-18, IL-10, and TNF (see Figure S1
in the Supplemental Data available online). Taken
together, these data show that PGN stimulation of
NOD2-deficient APCs mediated by TLR2 signaling re-
sults in enhanced production of IL-12p70 and, in turn,
leads to enhanced differentiation of naive Ag-specific
CD4+ T cells into IFN-g-producing CD4+ T cells. It should
be noted that the relatively greater enhancement of IL-
12p70 as compared to IFN-g in the cultures containing
NOD2-deficient versus NOD2-intact APCs was probably
due to the fact that costimulation via CD40 ligand-CD40
is more important for IL-12p70 production than for IFN-g
under these circumstances.
PGN Is Acting as a TLR2 Agonist in the Studies
of NOD2-Deficient APCs
Some investigators have suggested that contaminants
present in semipurified (commercially available) PGN
(such as lipoteichoic acid) rather than PGN itself ac-
counts for the TLR2 stimulation by such PGN (Travassos
et al., 2004). However, other investigators claim that
contaminant-free PGN can be obtained that retains
TLR2 stimulating activity (Dziarski and Gupta, 2005).
In view of this uncertainty, we next conducted studies
to verify that the NOD2 regulation of in vitro PGN
responses shown above was in fact related to TLR2
signaling. In an initial set of studies addressing this
issue, we stimulated CD11b+ cells from littermate control,
NOD2-deficient, and NOD2 and TLR2 double-deficient
(NOD2-TLR2-deficient) mice with commercially available
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475Figure 1. Increased IL-12 Production by NOD2-Deficient APCs Stimulated with PGN Leads to Enhanced Differentiation of Naive Ag-Specific
CD4+ T Cells into Th1 Cells
(A–C) Splenic CD4+ T cells (1 3 106/ml) recognizing the 323–339 peptide fragment of ovalbumin (OVA323-339 peptide) in the context of IA
b were
isolated from OT-II transgenic mice. The cells were then cultured in vitro with 0.5 mM of OVA323-339 peptide presented by splenic CD11b
+ cells (13
106/ml) from NOD2-intact or NOD2-deficient mice. These cultures were carried out in the presence of various TLR or NOD ligands including: LPS,
a TLR4 ligand; PGN from Staphylococcus aureus (PGN S), PGN from Escherichia coli (PGN E), and Pam3CSK4 (Pam), TLR2 ligands; dsRNA,
a TLR3 ligand; Flagellin, a TLR5 ligand; Loxoribine (Lox), a TLR7 ligand; CpG, a TLR9 ligand; and MDP, a NOD2 ligand. Culture supernatants
were harvested at 48 hr for IL-12p70 (A) assay and at 72 hr for IFN-g (B) and IL-13 (C) assays.
(D and E) Splenic CD11b+ cells (13 106/ml) from littermate control, NOD2-deficient, and NOD2 and TLR2 double-deficient mice were stimulated
in vitro with commercial PGN (10 mg/ml) ([D], top) or purified PGN (50 mg/ml) ([E], top) in the presence of control Ab or neutralizing TLR2 Ab (100 mg/
ml). Culture supernatants were harvested at 48 hr for assay of IL-12p70. Splenic CD4+ T cells (1 3 106/ml) isolated from OT-II transgenic mice
were stimulated in vitro with 0.5 mM of OVA323-339 peptide presented by splenic CD11b
+ cells (13 106/ml) from littermate control, NOD2-deficient,
and NOD2 and TLR2 double-deficient mice in the presence of commercial PGN (10 mg/ml) ([D], bottom), purified PGN (50 mg/ml) ([E], bottom),
control Ab or neutralizing anti-TLR2 Ab (100 mg/ml). Culture supernatants were harvested at 72 hr for assay of IFN-g. *p < 0.05, **p < 0.01, com-
pared with the results of cytokine concentrations of the culture containing APCs from littermate control mice. Data shown are representative of
two separate experiments. Data are expressed as mean 6 SD.PGN (as in the experiments described above). We found
that whereas the NOD2-deficient cells produced in-
creased amounts of IL-12p70 as compared to NOD2-
intact cells, NOD2-TLR2-deficient cells produced even
less IL-12p70 than NOD2-intact cells (Figure 1D, top).
In addition, a similar result was obtained with cultures
in CD11b+ cells containing OVA323-339-specific T cells
and OVA323-339 peptide in relation to IFN-g production
(Figure 1D, bottom): again, enhancement of such pro-
duction seen in cultures containing NOD2-deficient
CD11b+ cells was abolished in cultures containing
NOD2-TLR2-deficient cells. Finally, we inhibited TLR2
signaling with a monoclonal antibody (mAb) recognizing
TLR2, and again the enhancement of either IL-12p70
or IFN-g production was inhibited in the two-culturesystems (Figure 1D). These results show that in the
absence of TLR2 signaling, PGN (or contaminants con-
tained therein) cannot induce an IL-12 response that
can be regulated by NOD2 signaling.
In a complementary approach to this issue, we stimu-
lated CD11b+ cells (or CD11b+ cells plus OVA323-339-
specific T cells and OVA323-339 peptide) with a prepara-
tion of purified PGN that was free of lipoteichoic acid
(Dziarski and Gupta, 2005), and again cultures contain-
ing NOD2-deficient CD11b+ cells manifested enhanced
IL-12p70 or IFN-gproduction compared to those contain-
ing NOD2-intact cells, and the enhancing effect was
abolished in cultures containing NOD2-TLR2-deficient
cells (Figure 1E). Furthermore, addition of TLR2 mAb
again prevented the enhancement in cultures containing
Immunity
476Figure 2. Apoptosis and Cell Division of OVA-Specific CD4+ T Cells Stimulated in the Presence of TLR or NOD Ligands
Naive OVA323-339 peptide-specific CD4
+ T cells were isolated from OT-II transgenic mice and then stimulated in vitro with 0.5 mM of OVA323-339
peptide presented by splenic CD11b+ cells from NOD2-intact or NOD2-deficient mice in the presence of various TLR or NOD ligands as de-
scribed in Figure 1.
(A) Flow cytometric analysis of Annexin V versus propidium iodide (PI) staining of naive OVA-specific CD4+ T cells. Cells were cultured for 48 hr
and then stained with FITC-conjugated Annexin V, PE-conjugated Vb5 mAb, and PI; gate was set on CD4+Vb5+ T cells; the number in each figure
indicates the percentage of cells in the corresponding quadrant.
(B) Flow cytometric analysis of OVA323-339 peptide-specific CD4
+ T cells. T cells were incubated with 2 mM of CFSE and cultured for 72 hr as de-
scribed in (A). Green indicates T cells in cell cultures containing NOD2-intact CD11b+ cells; orange indicates T cells in cultures containing NOD2-
deficient CD11b+ cells. The number in each figure indicates the percentage of cells in the gate M1.
(C) Proliferative responses of naive OVA323-339 peptide-specific CD4
+ T cells evaluated by 3H thymidine incorporation. T cell cultured as de-
scribed in (A) were incubated for 72 hr with addition of 1 mCi of 3H thymidine during the final 16 hr. **p < 0.01, T cell proliferation in cultures con-
taining NOD2-deficient APCs compared with T cells in cultures containing NOD2-intact APCs. Data shown are representative of two separate
experiments. Data are expressed as mean 6 SD.NOD2-deficient cells. Thus, even with purified PGN,
TLR2 signaling was necessary to produce a response
that could be regulated by NOD2.
PGN-Stimulated NOD2-Deficient APCs Is Associated
with Decreased Apoptosis and Increased
Proliferation of CD4+ T Cells
Previous studies have shown that IL-12 not only drives
Th1 differentiation but also inhibits T cell apoptosis of
newly differentiated cells and thereby enhances their
survival (Fuss et al., 1999; Watanabe et al., 2003). We
therefore asked whether presentation of OVA peptide
by PGN-stimulated NOD2-deficient APCs (CD11b+ cells)
to OVA-specific CD4+ T cells (OT-II T cells) affects the
apoptosis of the T cells. Accordingly, we cultured
OVA-specific CD4+ T cells with PGN-stimulated NOD2-deficient or NOD2-intact APCs in the presence of
OVA323-339 peptide for 2 days and then measured the
percentage of Annexin V+ and propidium iodide2 (PI2)
CD4+ T cells in the cell culture by flow cytometry with
the Vb5+ marker to limit the analysis to responding
OVA-specific CD4+ T cells. T cells cultured with NOD2-
deficient APCs exhibited markedly less apoptosis than
T cells cultured with NOD2-intact APCs in the presence
of PGN (Figure 2A). In addition, there was no difference
in the percentage of apoptotic OVA-specific CD4+
T cells when the latter were cultured with LPS-MDP-
Pam3CSK4- or CpG-stimulated NOD2-deficient versus
NOD2-intact APCs.
An additional possible effect of increased IL-12 pro-
duction by PGN-stimulated NOD2-deficient APCs pre-
senting an Ag to CD4+ T cells is that the latter manifest
Antigen-Specific Colitis in NOD2-Deficient Mice
477increased proliferation. To explore this possibility, we
assessed proliferation of OVA-specific CD4+ T cells pre-
sented OVA323-339 peptide by TLR-stimulated NOD2-de-
ficient or NOD2-intact APCs with carboxyfluorescein di-
acetate succinimidyl ester (CFSE) to assess by flow
cytometry the number of cell divisions occurring in the
cultures after 3 days. Addition of OVA peptide to the cul-
tures led to greater number of cell divisions of OVA-spe-
cific CD4+ T cells presented Ag by PGN-stimulated
NOD2-deficient APCs than T cells presented Ag by
PGN-stimulated NOD2-intact APCs (Figure 2B). In con-
trast, LPS or CpG stimulation of NOD2-deficient or
NOD2-intact APCs led to equal levels of proliferation of
OVA-specific CD4+ T cells. These results were con-
firmed by 3H-thymidine incorporation assays. Thus,
OVA-specific CD4+ T cells exhibited increased prolifera-
tion when presented OVA peptide by NOD2-deficient
APCs in the presence of PGN as compared to T cells
presented peptide by NOD2-intact APCs (Figure 2C).
Finally, to show that these effects on CD4+ T cell pro-
liferation and IFN-g production occur as a result of en-
hanced IL-12 production, we added IL-12p40 mAb to
cultures containing NOD2-deficient APCs, OVA-specific
CD4+ T cells, and OVA peptide and showed that such
addition led to substantially reduced IFN-g production
(Figure S2A), increase in the percentage of Annexin
V+PI2 apoptotic cells (Figure S2B), and decreased T
cell proliferation (Figure S2C). It should be noted that
while the addition of IL-12p40 mAb to cultures contain-
ing NOD2-deficient APCs did not lead to complete inhi-
bition of IFN-g production, the level of inhibition ob-
tained was equal to that seen in cultures containing
NOD2-intact APCs, suggesting that it was not related
to NOD2 presence or absence. It may instead be due
to the fact that in this in vitro system, the cells are under
a strong activation stimulus involving both TLR ligand
and Ag signaling and thus are difficult to completely in-
hibit in a competitive assay. In summary of this series of
studies, we conclude that the enhanced IL-12 produc-
tion by PGN-treated NOD2-deficient APCs noted above
increases not only IFN-g production by responding
CD4+ T cells, but also the survival and proliferation of
the latter cells.
NOD2-Deficient APCs Stimulated with E. coli
Expressing OVA Induce Enhanced IFN-g Production
The above studies revealing enhanced adaptive re-
sponses in T cells presented an Ag by PGN-stimulated
APCs lacking NOD2 could apply to Ags associated
with the intestinal microflora. As a first step in the explo-
ration of this possibility, we asked whether NOD2-intact
and NOD2-deficient APCs differ in their capacity to re-
spond to Ags (proteins) associated with bacteria. For
this purpose, we stimulated NOD2-intact and NOD2-de-
ficient APCs with recombinant E. coli expressing either
OVA (ECOVA) or a control antigen, LACZ (ECLACZ)
(Yoshida et al., 2001, 2002), in the presence of OVA-spe-
cific CD4+ T cells. OVA-specific CD4+ T cells stimulated
with ECOVA and NOD2-deficient APCs produced mark-
edly more IFN-g than those stimulated with ECOVA and
NOD2-intact cells (Figure 3A). In contrast, no difference
was seen in IFN-g production when the cells were stim-
ulated with OVA protein and NOD2-deficient or NOD2-
intact APCs, suggesting that enhancement of IFN-gproduction with stimulation by NOD2-deficient APCs
requires the stimulating Ag to be part of a bacteria that
is capable of concomitant stimulation of the APCs via
TLRs. On the other hand, the latter stimulation alone
was not sufficient for IFN-g production, as indicated
by the fact that little production was seen in the pres-
ence of bacteria expressing an irrelevant antigen
(LACZ). Thus, these results indicate that NOD2-deficient
APCs can induce an Ag-specific Th1 response to a
bacterial Ag in vitro when exposed to the intestinal
microflora.
In a final set of in vitro studies involving stimulation by
whole organisms, we asked whether stimulation of
NOD2-deficient APCs by ECOVA requires an intact
TLR2 signaling pathway. To this end, we determined
whether neutralizing TLR2 mAb (Meng et al., 2004) or
TLR4 mAb (Poltorak et al., 2000) blocks ECOVA stimula-
tion of CD11b+ cells. We found that addition of TLR2
mAb to the culture reduced IFN-g production in a
dose-dependent manner, whereas addition of TLR4 Ab
had only a marginal effect that lacked statistical signifi-
cance (Figure 3B). These data therefore indicate that the
enhanced Th1 responses obtained in cultures of
Figure 3. IFN-g Production by OVA-Specific CD4+ T Cells Stimu-
lated with ECOVA in the Presence of Splenic CD11b+ Cells
OVA323-339 peptide-specific CD4
+ T cells were isolated from OT-II
transgenic mice and then stimulated in vitro with various doses of
ECOVA or ECLACZ in the presence of splenic CD11b+ cells from
NOD2-intact or NOD2-deficient mice. As controls, OT-II CD4+ T cells
were stimulated with OVA protein (1 or 10 mg/ml) in the presence of
splenic CD11b+ cells from NOD2-intact or NOD2-deficient mice.
(A) IFN-g secretion into culture supernatants collected at 96 hr and
measured by ELISA. **p < 0.01, *p < 0.05, compared with the results
of cytokine concentrations of the culture containing NOD2-intact
APCs.
(B) IFN-g secretion into culture supernatants of cells cultured as
above, but in the presence of neutralizing antibodies specific for
TLR2 or TLR4. **p < 0.01, *p < 0.05, compared with the results of cy-
tokine concentrations of the culture containing control Ab. Data
shown are representative of two separate experiments. Data are
expressed as mean 6 SD.
Immunity
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require TLR2 signaling.
NOD2-Deficient Mice Are Susceptible
to the Development of ECOVA Colitis
The enhanced Th1 responses of Ag-specific CD4+ T
cells stimulated by NOD2-deficient APCs in the pres-
ence of recombinant E. coli expressing the Ag led us
to determine whether Ag-specific responses to a bacte-
rial antigen could serve as the basis for colitis in NOD2-
deficient mice. To explore this possibility, we turned to
a murine model of colitis in which the colonic inflamma-
tion is induced in recipient mice adoptively transferred
OVA-specific CD4+ T cells from OVA-T cell receptor
transgenic mice and then administered ECOVA (Wata-
nabe et al., 2005b; Yoshida et al., 2001, 2002).
In the studies performed here, NOD2-deficient or
NOD2-intact mice were adoptively transferred OVA pep-
tide-specific CD4+ T cells from OT-II mice (OVA-specific
T cells) and then immunized subcutaneously with
OVA+CFA (complete Freund’s adjuvant) to expand the
population of OVA-specific T cells (a necessary step in
these nonimmunodeficient recipient mice). 3 days after
immunization, the mice were administered ECOVA or
ECLACZ per rectum (Figure S3A).
In preliminary studies we assessed whether subcuta-
neous immunization with OVA+CFA to expand the trans-
ferred OVA-specific CD4+ T cell population has a differ-
ential effect on the expansion of OVA-specific CD4+ T
cells in the draining lymph nodes in NOD2-deficient ver-
sus NOD2-intact mice. OVA+CFA treatment greatly ex-
pands the percentage of CD4+Vb5+ T cells (i.e., T cells
specific to OVA323-339 peptide) in draining lymph nodes
of both NOD2-deficient and NOD2-intact mice, and
this expansion is equivalent in the two types of mice
(Figure S3B). In addition, the expanded cell population
produced equivalent amounts of IFN-g and IL-4 (Fig-
ure S3C). Thus, the use of OVA+CFA to expand the
OVA-specific CD4+ did not lead to a differential increase
in OVA-specific CD4+ T cells in NOD2-deficient mice.
NOD2-deficient mice adoptively transferred OVA-spe-
cific T cells and challenged with ECOVA but not ECLACZ
developed significant colitis, whereas littermate control
mice did not develop colitis when challenged by either
recombinant bacterium. First, NOD2-deficient mice ex-
hibited significantly more weight loss in the 3 days after
ECOVA challenge than NOD2-intact mice after a similar
type of challenge, whereas neither types of mice lost
a significant amount of weight after ECLACZ challenge
(p < 0.05, Figure 4A). Similarly, histologic examination
of colon tissue harvested on day 3 or 5 after ECOVA or
ECLACZ administration revealed obvious and severe in-
flammation in the colons of NOD2-deficient mice admin-
istered ECOVA but not in those administered ECLACZ;
in contrast, administration of these recombinant organ-
isms to NOD2-intact mice led to only a small increase in
the number of infiltrating mononuclear cells in the co-
lons of mice administered ECOVA and no increase in
infiltration cells in the colons of mice administered
ECLACZ (Figure 4B). In severe lesions of NOD2-deficient
mice challenged with ECOVA, the inflammation was
characterized by massive infiltration of mononuclear
cells and destruction of crypt architecture. Of interest,
however, these inflammatory lesions were discontinu-ous, ‘‘skip’’ lesions, as noted previously in ECOVA colitis
(Yoshida et al., 2001, 2002). To obtain semiquantitative
estimates of these histologic changes, we derived colitis
scores for each experimental group based on crypt loss,
cellular infiltration, and the depth of the inflammation
(Watanabe et al., 2005b; Yoshida et al., 2001, 2002). Co-
lons harvested on day 3 or 5 from NOD2-deficient mice
challenged with ECOVA exhibited a significantly higher
score compared with those of the other three groups
(p < 0.01, Figure 4C).
Second, we measured the clonal expansion of OVA-
specific CD4+ T cells in the mesenteric lymph node
(MLN) and colonic lamina propria (LP) of the adoptively
transferred NOD2-deficient or NOD2-intact mice chal-
lenged with ECOVA and ECLACZ. The percentage of
OVA-reactive CD4+Vb5+ T cells was markedly increased
only in the MLN and LP of NOD2-deficient mice chal-
lenged with ECOVA (Figure 5A). Since the total number
of MLN cells and LP lymphocytes were also increased
in these mice (data not shown), these data strongly sug-
gest that ECOVA induces a massive expansion of OVA-
specific CD4+ T cells in the intestine of NOD2-deficient
mice.
Third and finally, we assessed the production of cyto-
kines in the adoptively transferred NOD2-deficient and
NOD2-intact mice after being challenged with ECOVA
and ECLACZ. In these studies, MLN or LP cells were iso-
lated from tissues of NOD2-deficient and NOD2-intact
mice on day 3 after ECOVA or ECLACZ challenge and
then restimulated ex vivo with OVA peptide and PGN
to induce IFN-g or IL-12 production. LP cells obtained
from ECOVA-challenged NOD2-deficient mice exhibited
a great increase in IL-12p70 production after stimulation
with OVA peptide and PGN, as compared to LP cells ob-
tained from the various control mice (Figure 5B). Despite
the fact that the cells were cultured only 3 days after the
initiation of the inflammation, this increase was accom-
panied by a small increase in IL-23 secretion (data not
shown). Furthermore, both MLN and LP cells from
NOD2-deficient mice exhibited a massive increase in
IFN-g secretion after ECOVA challenge as compared
to cells from NOD2-intact mice or cells from either
type of mice challenged with ECLACZ (Figure 5C, left).
In contrast, there was no significant difference in the
production of IL-10 or TNF at this time point (data not
shown). IL-4 was below the detection limit in every
group. In contrast, stimulation of the same cells with
a polyclonal stimulant, CD3 mAb, did not lead to signif-
icant differences in IFN-g production by cells from the
various mouse groups, suggesting that only OVA-spe-
cific Th1 cells played a role in the development of the co-
litis (Figure 5C, right). Taken together, these data pro-
vide strong support for the idea that NOD2-deficient
mice are indeed more susceptible to colitis than their
wild-type counterparts and, surprisingly, the colitis can
be induced by a microbial Ag provided that the mouse
is responsive to that Ag.
The marked increase of Th1 cytokines such as IL-12
and IFN-g associated with the development of ECOVA
colitis in NOD2-deficient mice suggested to us that
this colitis was driven by IL-12. To explore this question,
we determined whether neutralization of these cyto-
kines by an IL-12p40 mAb could prevent the develop-
ment of the colitis. In these studies, NOD2-deficient
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NOD2-intact or NOD2-deficient mice were adoptively transferred OVA-specific CD4+ T cells (53 106/mouse) (day24) and on the next day sub-
jected to subcutaneous immunization with OVA+CFA (day 23). 3 days later (day 0), the mice were administered intrarectal ECOVA or ECLACZ
after intrarectal treatment with 50% ethanol. The mice were then administered intrarectal recombinant E. coli every day during the subsequent
observation period.
(A) Changes of body weights in the mice of each group. *p < 0.05, compared with the results of body weights of the mice in other groups. Data
shown are the combined results of two separate experiments (n = 5 in each group) and are expressed means 6 SD.
(B) Representative H&E-stained colonic tissue of the mice on day 3 and 5.
(C) Colitis scores derived from colons harvested on day 3 and day 5. **p < 0.01, comparing colitis score of NOD2-deficient mice with colitis scores
of mice in any of other groups. Data are expressed as mean 6 SD.mice were administered a neutralizing IL-12p40 mAb
that recognizes both IL-12 and IL-23 or control Ab at
the indicated time points (see Experimental Proce-
dures). While marked body weight loss was seen in
NOD2-deficient mice treated with control Ab and chal-
lenged with ECOVA, little body weight loss was seen in
NOD2-deficient mice treated with IL-12p40 mAb and
challenged with ECOVA (Figure 6A). Furthermore, IL-
12p40 treatment prevented the development of histo-
logic evidence of colitis (Figure 6B). IL-12p40 mAb treat-
ment was associated with a level of IFN-g production by
MLN cells from ECOVA-challenged mice equivalent to
that seen in ECLACZ-challenged mice (Figure 6C). Fi-
nally, IL-12p40 mAb treatment effectively reduced pro-
duction of both IL-12p70 and IL-23 by MLN cells stimu-
lated with OVA peptide and PGN (data not shown).
Taken together, these data provide strong evidence
that development of ECOVA colitis in NOD2-deficient
mice depends upon IL-12 and possibly IL-23 production
by APCs.NOD2-TLR2 Double-Deficient Mice Are Resistant
to the Development of ECOVA Colitis
Based on the in vitro studies described above and stud-
ies described previously (Watanabe et al., 2004), an un-
derlying premise of the above findings in ECOVA colitis
is that NOD2-deficient mice with such colitis are mount-
ing a dysreglated response to a TLR2 ligand associated
with the recombinant E. coli, namely, PGN. To address
this issue, in a final series of studies we determined
whether ECOVA colitis can be induced in NOD2-TLR2
double-deficient (NOD2-TLR2-deficient) mice. Accord-
ingly, we examined colitis induction as described above
in four groups of mice administered either intrarectal
ECLACZ or ECOVA: littermate control, NOD2-deficient,
TLR2-deficient, and NOD2-TLR2-deficient mice. As be-
fore, OVA-specific CD4+ T cells (OT II T cells) were trans-
ferred to each mouse prior to intrarectal recombinant
E. coli administration. ECOVA colitis was indicated by the
occurrence of weight loss, developed in NOD2-deficient
mice as before, whereas NOD2-TLR2-deficient mice
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Mesenteric lymph node cells and colonic lamina propria cells were isolated from mice administered ECOVA or ECLACZ on day 3 after admin-
istration.
(A) Flow cytometric analysis of mesenteric lymph node cells and colonic lamina propria lymphocytes stained with PE-conjugated CD4 mAb and
FITC-conjugated Vb5 mAb. Dead cells were excluded by PI-staining. The number in each figure shows the percentage of CD4+Vb5+ T cells (OVA-
specific CD4+ T cells).
(B) Concentrations of IL-12p70 in supernatants of cultures of colonic lamina propria cells stimulated with OVA323-339 peptide (0.5 mM) together
with PGN (10 mg/ml) for 48 hr. Data are expressed as mean6 SD. *p < 0.05, **p < 0.01, compared with the results of NOD2-intact mice treated with
ECOVA.
(C) Concentrations of IFN-g in supernatants of cultures of mesenteric lymph node cells and colonic lamina propria cells stimulated with CD3 mAb
(2 mg/ml) or OVA323-339 peptide (0.5 mM) for 60 hr. Results are representative one of two separate experiments (n = 5 in each group). Data are
expressed as mean 6 SD. **p < 0.01, NOD2-deficient mice compared with the NOD2-intact mice.exhibited only minor weight loss (Figure 7A). In addition,
upon histological analysis, severe colitis characterized
by massive infiltration of inflammatory cells along with
loss of mucosal architecture was seen in NOD2-defi-
cient mice administered ECOVA but not in the other
mouse groups including the NOD2-TLR2-deficient
group (Figure 7B). In particular, in the NOD2-TLR2-defi-
cient mice, cellular infiltration was greatly decreased
compared to the NOD2-deficient mice and manifested
itself only as an occasional and isolated island of inflam-
mation; loss of mucosal architecture was not seen.
These clinical findings correlated with immunologic fea-
tures. Thus, clonal expansion of OVA-specific CD4+
T cells was greatly reduced in the MLN of NOD2-TLR2-
deficient mice challenged with ECOVA as compared
with that of NOD2-deficient mice (Figure 7C). In addition,these differences were corroborated by studies show-
ing that MLN cells from NOD2-deficient mice produced
increased amounts of IFN-g ex vivo upon stimulation
with OVA peptide, whereas cells from NOD2-TLR2-defi-
cient did not (Figure 7D). This lack of significant ECOVA
colitis in the double-deficient mice strongly suggests
that TLR2 stimulation via PGN in the ECOVA is neces-
sary for the development of ECOVA colitis in NOD2-
deficient mice.
Discussion
In previous studies, we showed that NOD2-deficient
APCs manifest enhanced PGN-induced IL-12p70 re-
sponses as compared to NOD2-intact APCs (Watanabe
et al., 2004). In studies that enlarge on this finding, we
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481Figure 6. Development of Colitis in NOD2-Deficient Mice Challenged with ECOVA Depends upon IL-12
NOD2-deficient mice were administered ECOVA or ECLACZ as described in Figure 4. Mice received intraperitoneal injection of IL-12p40 mAb or
control Ab (1 mg) on day 21 and day 2.
(A) Changes of body weight of the mice in each group (n = 6). Results are expressed mean 6 SD. *p < 0.05, compared with the results of body
weights of the mice in other groups.
(B) H&E-stained colonic tissue of the mice administered ECOVA or ECLACZ harvested on day 4.
(C) Concentrations of IFN-g in supernatants of cultures of mesenteric lymph node cells stimulated with OVA323-339 peptide (0.5 mM) for 60 hr.
Results are expressed as mean 6 SD. **p < 0.01, compared with the results of NOD2-deficient mice treated with ECLACZ.now show that naive OVA-specific CD4+ T cells pre-
sented OVA peptide by PGN-stimulated APCs from
NOD2-deficient mice exhibit enhanced Th1 (IFN-g) re-
sponses. Similarly, we show that naive OVA-specific
CD4+ T cells also exhibit enhanced Th1 responses
when cultured with NOD2-deficient APCs in the pres-
ence of a recombinant E. coli expressing OVA (ECOVA).
In this case, the E. coli organisms were the source of the
stimulating PGN as well as the OVA peptide being pre-
sented. These in vitro studies set the stage for in vivo
studies relating to the induction of colitis in NOD2-defi-
cient mice. Here we demonstrated that NOD2-deficient
mice but not NOD2-intact mice adoptively transferred
with OVA-specific CD4+ T cells and then administered
recombinant E. coli expressing OVA (ECOVA) per rec-
tum develop colitis. In addition, development of this
type of colitis is virtually absent in NOD2-TLR2 double-
deficient mice or NOD2-deficient mice treated with IL-
12p40 mAb. Thus, these in vivo studies show that a dys-
regulated innate immune response to PGN caused by
NOD2 deficiency can act via a specific adaptive immune
response to an Ag associated with a gut commensal to
cause mucosal inflammation.
The concept that both innate and adaptive immune re-
sponses may be necessary for the induction of mucosal
inflammation as demonstrated here is presaged by pre-vious studies of experimental models of colitis. It has
been shown, for instance, that hapten-induced (TNBS)
colitis mediated by Th1 responses is readily induced in
mouse strains with a genetic susceptibility locus on
chromosome 11 that also encodes a gene that gives
rise to an enhanced LPS-induced IL-12 response. It
thus appears that an innate IL-12 response to an TLR4
agonist, or possibly some other TLR response to an as
yet undefined bacterial component, sets the stage for,
and, indeed, is a necessary accompaniment of colitis in-
duced by a specific hapten Ag, TNBS (Bouma et al.,
2002). Similarly, mice with Stat3 deficiency and therefore
with impaired IL-10 responses manifest an IL-12-driven
colitis probably due to the faulty immunoregulation that
accompanies the IL-10 defect (Kobayashi et al., 2003).
Of interest to the present discussion, the mice with
Stat3 deficiency did not develop colitis if they were inter-
bred with mice lacking TLR4 expression; thus, in this
model, an innate immune response again mediated by
LPS is required to drive the development of colitis. Fur-
thermore, in this model, development of colitis was not
seen in mice lacking T cells, suggesting the importance
of adaptive responses in addition to excessive IL-12
production in innate responses. Taken together, these
models indicate that innate responses play a critical
role in mucosal inflammation, both in situations in which
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Littermate control, NOD2-deficient, TLR2-deficient, and NOD2-TLR2-deficient mice were administered ECOVA or ECLACZ as described in
Figure 4.
(A) Changes of body weight of the mice in each group (n = 5). Results are expressed as mean6 SD. *p < 0.05, compared with the results of body
weights of the mice in other groups.
(B) H&E-stained colonic tissue of the mice administered ECOVA harvested on day 4. Histology of NOD2-deficient mice with colitis highly indic-
ative of inflammation seen throughout the colon tissue; histology of NOD2-TLR2-deficient mice indicating occasional island of cellular infiltration;
most of the tissue was free of inflammation.
(C) Flow cytometric analysis of mesenteric lymph node cells stained with PE-conjugated CD4 mAb and FITC-conjugated Vb5 mAb. Dead cells
were excluded by PI staining. The number in each figure shows the percentage of CD4+Vb5+ T cells (OVA-specific CD4+ T cells).
(D) Concentrations of IFN-g in supernatants of cultures of mesenteric lymph node cells stimulated with CD3 mAb (2 mg/ml) or OVA323-339 peptide
(0.5 mM) for 60 hr. Results are expressed as mean 6 SD. **p < 0.01, compared with the results of littermate control mice treated with ECOVA.disease is caused by an excessive effector Th1 re-
sponse (mice with TNBS colitis) as well as in situations
in which disease is due to lack of regulatory cytokine
responses such as IL-10 (Stat32/2-Tlr42/2 mice).
A notable feature of ECOVA colitis in NOD2-deficient
mice is that the colitis does not occur or is greatly de-
creased in NOD2-TLR2 double-deficient mice, i.e., in
the absence of TLR2 signaling. This has several implica-
tions. First, it indicates that the generation of IL-12 and
other features of the Th1 response in ECOVA colitis is
not due to a defect in NOD2 signaling that is indepen-
dent of PGN interaction and signaling through TLR2. In-
stead, it adds support to the idea that the colitis is in fact
due to a dysregulated TLR2 response related to defec-
tive NOD2 signaling. Such dysregulation could be due
to the possibility that intact NOD2 signaling results in
the elaboration of one or more factors that normally reg-ulate TLR2 signaling and thereby downmodulate the IL-
12 response that results from such signaling. Second, it
shows that a gram-negative organism such as E. coli
that contains a relatively small amount of the TLR2 li-
gand, PGN (or TLR2 ligands associated with PGN), in
its coat (as compared to gram-positive organisms) is
sufficient to cause colitis in NOD2-deficient mice. This
can be due to the fact that the amount of PGN in the
ECOVA, although relatively small, is sufficient for the
induction of inflammation or that the inflammation is
driven by PGN derived from other organisms as well.
Third and finally, the attenuation of ECOVA colitis in
the absence of TLR2 implies that an innate immune re-
sponse of mucosal APCs to PGN (such as their produc-
tion of IL-12) is sufficient for the induction of colitis spe-
cific to an Ag associated with the commensal microflora.
By the same token, dysregulation of the response of
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necessary for the occurrence of colitis in this model.
One caveat to this last point is that the ECOVA colitis in-
duced here was a transient colitis (see Discussion be-
low), and it may be that in a more prolonged colitis due
to deficient NOD2 function, dysregulation of other TLR
responses will be seen as well.
The ECOVA-induced colitis in NOD2-deficient mice
described here can be considered a model of human
Crohn’s disease associated with NOD2 abnormalities,
inasmuch as the latter occurs not only in patients with
disease of the terminal ileum, but also those with ileo-
colonic disease or even colonic disease alone (Lesage
et al., 2002). In addition, the model resembles the human
disease on several immunologic grounds. First, the ex-
perimental model is associated with a genetic defect
that, as discussed above, leads to an abnormal innate
immune response characterized by the development
of APCs overproducing IL-12. Second, the model is
characterized by an IL-12-driven Th1 T cell-mediated in-
flammation associated with increased Ag-specific T cell
proliferation and survival (the latter due to decreased
apoptosis). This was shown by the fact that increased
numbers of OVA-specific T cells could be identified in
LP and MLN of NOD2-deficient mice after ECOVA chal-
lenge and, as shown previously, is traceable in part to
the known antiapoptotic effect of IL-12 (Fuss et al.,
1999; Watanabe et al., 2003). Third and perhaps most
importantly, the model is associated with an inflamma-
tion induced by a nonpathogenic (commensal) organ-
ism, i.e., an E. coli that expressed an Ag relevant to the
adoptively transferred CD4+ T cells. These characteris-
tics are mirrored in Crohn’s disease in that the human in-
flammation is also marked by overproduction of IL-12 by
APCs in the lamina propria (Monteleone et al., 1997; Par-
ronchi et al., 1997) as well as the presence of Th1 effec-
tor cells producing IFN-g (Fuss et al., 1996). In addition,
as in the model, T cells in the lesions are resistant to ap-
optosis (Boirivant et al., 1999). Finally, in recent years,
Crohn’s disease has also been linked to abnormal re-
sponses to one or more Ags in the commensal organ-
isms of the mucosal microflora (Bouma and Strober,
2003; Strober et al., 2002). This is highlighted by emerg-
ing data that flagellins and perhaps other Ags associ-
ated with mucosal microflora may be involved in the de-
velopment of Crohn’s disease (Cong et al., 1998; Lodes
et al., 2004). These parallel findings in the model and
the human inflammatory bowel disease suggest that
Crohn’s disease associated with NOD2 mutations (and
perhaps other patients as well) is due to an abnormal in-
nate immune response leading to increased IL-12 re-
sponses of APCs coupled with an abnormal and exces-
sive IFN-g response to an Ag associated with a
commensal organism. In this formulation of disease
pathogenesis, while the mutations are necessary for
the occurrence of disease, they are not sufficient: a sec-
ond genetic or environmental factor that allows expan-
sion of CD4+ T cells recognizing a commensal Ag must
also be present for development of disease.
While ECOVA colitis in NOD2-deficient mice bears
many similarities to human Crohn’s disease, it also con-
tains some notable differences. One such difference
concerns the fact that TNF production was not in-
creased in NOD2-deficient mice with ECOVA colitis, re-flecting previous data that PGN-stimulated APCs from
such mice do not produce increased amounts of this cy-
tokine (Watanabe et al., 2004). This lack of TNF overpro-
duction contrasts with the massive TNF production seen
in Crohn’s disease and the response of patients to treat-
ment with TNF Ab therapy (Targan et al., 1997). One pos-
sible resolution of this discrepancy is that the ECOVA
colitis in NOD2-deficient mice represents an early or pri-
mordial form of Crohn’s disease and reflects the latter at
an early stage of disease development that is dependent
on IL-12 production but not TNF production. In this view,
it is only later when the disease results in additional
pathologic changes that one sees the TNF response.
A second difference between ECOVA colitis in NOD2-
deficient mice and Crohn’s disease is the transience of
the former and the persistence of the latter. One factor
that could explain this discordance is that the ECOVA
(the inciting organism) had only a narrow window of ac-
cess to potentially reactive mucosal cells in this model. It
should be noted, in this regard, that the ECOVA was ad-
ministered with ethanol only on day 0 of colitis induction
and therefore mucosal barrier function after the first or
second day may have been sufficient to exclude this or-
ganism from the internal milieu. In humans with Crohn’s
disease, the inciting organism may be both more persis-
tent than ECOVA and more capable of penetrating the
mucosal barrier such as the enteroadherent E. coli
said to be associated in some patients with the disease
(Martin et al., 2004).
In summary, the data described here provide insight
into the conditions necessary for the development of
Th1-mediated colitis in mice with an abnormality of
NOD2 function. In essence they show that a NOD2 ab-
normality leads to a defective innate immune response
involving APCs that gives rise to disease only in the
presence of T cells that mount an adaptive immune re-
sponse to an Ag in the mucosal microflora. While the co-
litis induced in NOD2-deficient mice by administration of
ECOVA requires provision of exogenous T cells specific
for OVA, it is conceivable that humans with NOD2 muta-
tions spontaneously develop T cells that react with spe-
cific Ags in the bacterial microflora because of environ-
mental factors or additional genetic factors. Finally, in
relating a genetically determined Th1 response and sub-
sequent inflammation to an Ag in the bacterial micro-
flora, these data provide additional support for the con-
cept that Crohn’s disease results from an abnormality in
mucosal unresponsiveness to microfloral components.
Experimental Procedures
Mice
6- to 10-week-old male Card15+/+ and Card152/2mice (Pauleau and
Murray, 2003) were used. Tlr22/2mice were kindly provided by Dr. S.
Akira and crossed to Card152/2 mice to generate Card152/2Tlr22/2
mice. OT-II mice were purchased from Jackson Laboratory and have
a transgenic Va2Vb5 TCR specific for the OVA323–339 epitope in the
context of IAb. Animal use adhered to National Institutes of Health
Animal Care Guidelines.
Cell Isolation and Stimulation
Total splenocytes were isolated as described previously (Watanabe
et al., 2002). CD11b+ cells were isolated from the spleen of NOD2-
deficient or NOD2-intact mice by positive selection by means of
anti-mouse CD11b microbeads (Miltenyi BioTech). CD4+ T cells
were isolated from the spleen of OT-II mice by positive selection
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484with anti-mouse CD4 microbeads (Miltenyi BioTech). The purity of
each fraction was >90% by flow cytometry. OT-II CD4+ T cells (1 3
106/ml) were stimulated with OVA323-339 peptide (0.5 mM) presented
by splenic CD11b+ cells (1 3 106/ml) from NOD2-deficient and
NOD2-intact mice. LPS (1 mg/ml, Sigma), PGN from Staphylococcus
aureus (10mg/ml, Fluka), PGN fromEscherichia coli (10mg/ml, Invivo-
Gen), Pam3CSK4 (1 mg/ml, InvivoGen), dsRNA (50 mg/ml, Invivo-
Gen), Flagellin (1 mg/ml, InvivoGen), Loxoribine (100 mM, InvivoGen),
CpG (1 mM, InvivoGen), or MDP (10 mg/ml, Sigma) was added to this
culture. Purified PGN from Staphylococcus aureus was kindly pro-
vided by Dr. R. Dziarski (Dziarski and Gupta, 2005). Cells were incu-
bated in RPMI1640 medium containing 10% FCS for 48 or 72 hr.
Unless specified, the concentrations described above were used
throughout the study. Culture supernatants were harvested at 72
hr for IFN-g, IL-4, IL-10, and IL-13 and 48 hr for TNF, IL-18, and IL-
12p70. Concentrations of cytokines were determined with the use
of ELISA kits purchased from Pharmingen (IFN-g, IL-4, IL-10, IL-
18, and TNF) and R&D Systems (IL-13 and IL-12p70). In this study,
apoptotic cell death and cell division of responder OT-II CD4+ T cells
were assessed by Annexin V binding assay and CFSE staining, re-
spectively, as described before (Watanabe et al., 2003). For Annexin
V and CFSE staining, cells were incubated for 48 and 72 hr, respec-
tively.
Flow Cytometry
PE-CD4 and FITC-Vb5 mAbs were purchased from Pharmingen.
Nonspecific binding of Abs was blocked by Fc-block mAb (2.4G2,
Pharmingen) and dead cells were excluded by PI staining. The anal-
ysis was performed on a Becton Dickinson FACS Caliber with CELL-
Quest II software.
Stimulation of Cells with ECOVA or ECLACZ
ECOVA and ECLACZ were prepared as described previously (Wata-
nabe et al., 2005b; Yoshida et al., 2001, 2002). OVA-specific CD4+ T
cells isolated from the spleen of OT-II mice were stimulated with sev-
eral doses of gentamycin-killed ECOVA or ECLACZ in the presence
of splenic CD11b+ cells from NOD2-deficient or NOD2-intact mice. In
some experiments, neutralizing Ab for TLR2 (eBioScience) (Meng
et al., 2004) or TLR4 (Imgenex) (Poltorak et al., 2000) was used at
the indicated dose.
Induction of Colitis
Littermate control, Card15-/- (NOD2-deficient), Tlr22/2, and
Card152/2Tlr22/2 (NOD2-TLR2-deficient) mice were adoptively
transferred with 5 3 106 CD4+ T cells purified from the spleen of
OT-II mice followed by subcutaneous immunization of OVA+CFA
in the footpad the next day. 3 days after the immunization, recipient
mice were challenged with intrarectal administration of ECOVA or
ECLACZ (13 109 colony-forming units) after pretreatment with intra-
rectal injection of 100 ml of 50% ethanol (day 0, Figure S3A). Mice
were challenged with intrarectal administration of the bacteria every
day and were treated with antibiotics in the drinking water contain-
ing 1.0 mg/ml of ampicillin (Sigma) and kanamycin (Sigma) (Wata-
nabe et al., 2005b; Yoshida et al., 2001, 2002). In some experiments,
mice were intraperitonealy injected with neutralizing Ab to murine IL-
12p40 (C17.8, 1 mg/mouse) or control Rat IgG (ICN) on day 1 and day
2. At the indicated time points, colon tissues were taken and fixed in
10% buffered formalin for histological analysis via hematoxylin and
eosin (H&E) staining. Histology score based on cell infiltration,
depth, and crypt loss was evaluated as previously described (Wata-
nabe et al., 2005b; Yoshida et al., 2001, 2002). At the indicated time
points, mesenteric lymph node cells and colonic lamina propria cells
were isolated as described previously (Watanabe et al., 2005b;
Yoshida et al., 2001, 2002). These cells (13 106/ml) were stimulated
with 0.5 mM of OVA323-339 peptide, 10 mg/ml of PGN, or 2 mg/ml of
CD3 mAb (Pharmingen) for 48 or 60 hr to measure the concentration
of IFN-g, IL-4, IL-10, IL-12p70, and TNF in the supernatants. Mesen-
teric lymph node cells and lamina propria cells were stained with PE-
CD4 mAb and FITC-Vb5 mAb for visualizing the population of OVA-
specific CD4+ T cells by flow cytometry. In some experiments,
mononuclear cells were isolated from the popliteal lymph nodes 3
days after the subcutaneous immunization of OVA+CFA at the foot-
pad. These lymph node cells (1 3 106/ml) were stimulated with
0.5 mM of OVA323-339 peptide for IFN-g and IL-4 assay.Statistical Analysis
Student’s t test was used to evaluate the significance of the differ-
ences. Statistical analysis was performed with the StatView v.4.5
program (Abacus Concepts, Berkeley, CA). A value of p < 0.05 was
regarded as statistically significant.
Supplemental Data
Supplemental Data include three figures and Supplemental Experi-
mental Procedures and can be found with this article online at
http://www.immunity.com/cgi/content/full/25/3/473/DC1/.
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